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Received October 22, 2012; accepted April 25, 2013AbstractBackground: High-resolution computed tomography (HRCT) has become increasingly popular recently and more pulmonary ground-glass
opacities (GGOs) are being identified. However, the treatment for these GGOs remains controversial. The purpose of this study was to retro-
spectively review the clinical and pathological characteristics and to demonstrate the longterm surgical outcomes in patients undergoing
resection for GGOs in our institute.
Methods: From January 2004 to December 2008, we enrolled 50 patients undergoing resection for solitary pulmonary GGOs of 3 cm or less at
Taipei Veterans General Hospital. Patients with a past history of lung cancer, or multiple GGOs at presentation, or GGOs accompanied by a solid
component of more than 50 percent were excluded. The patients were retrospectively reviewed and the rate and circumstances of survival were
analyzed.
Results: Of the 50 patients, 43 (86%) patients underwent surgery immediately after the GGO lesions were detected by the initial HRCT. Forty-six
(92.0%) patients were diagnosed with lung cancer. Of this group, there were 8 (17.4%) adenocarcinomas with lepidic predominant pattern, 13
(28.3%) adenocarcinomas with acinar predominant pattern, and 24 (52.2%) adenocarcinomas with papillary predominant pattern. There was one
adenocarcinoma that was mixed with small cell carcinoma. There was no surgical mortality overall, and the 5-year overall and disease-specific
survival rates were 97.5% and 100%, respectively.
Conclusion: The percentage of malignancy is high in pulmonary GGOs. Surgery results in an excellent prognosis in these patients.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Lung cancer is the leading cause of cancer-related mortality
around the world. When it is diagnosed, only a small number
of lung cancer patients present with early-stage disease that is
resectable by surgery. Most patients present with advanced
disease and are faced with a dismal prognosis and a life ex-
pectancy of less than 1e2 years.1e4 In recent years, more
people have undergone high-resolution computed tomography* Corresponding author. Dr. Wen-Hu Hsu, Division of Thoracic Surgery,
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cancer at an earlier stage. This has resulted in an increasing
number of patients being detected with pulmonary ground-
glass opacity (GGO) lesions that were not previously visual-
ized by conventional radiography methods.5,6 A GGO lesion is
characterized by an area of haziness with preservation of
bronchial and vascular margins.7,8 The pathological compo-
nents of GGOs have usually been diagnosed as papillary
adenocarcinomas, bronchioloalveolar carcinomas (BACs),
atypical adenomatous hyperplasias (AAHs), and organizing
pneumonias.9
Many patients with risk factors chose to undergo surgical
resection for the GGOs; however, management and treatmenthinese Medical Association. All rights reserved.
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there are only a few reports in the literature that present the
surgical outcomes of GGO lesions.10e12 In this study, we
retrospectively reviewed the clinical and pathological charac-
teristics and the surgical outcomes of patients undergoing
resection for GGOs in our institute.2. Methods
We retrospectively reviewed the chart records of our pa-
tients who presented with GGOs and received surgical resec-
tion at the Taipei Veterans General Hospital (Taipei, Taiwan)
between January 2004 and December 2008. Patients under-
going resection for a solitary pulmonary GGO for a tumor of
3 cm or less were included. For mixed GGOs, only nodules
with less than 50% solid part at the maximal lesion diameter
were included (Fig. 1). Patients with solid tumors were
excluded. Patients with a past history of lung cancer, multiple
GGOs at presentation, or GGOs accompanying large solid
tumor were also excluded.
All patients underwent physical examination, chest radio-
graph, and chest computed tomography (CT) scan. They also
provided extensive medical history information. Laboratory
studies, electrocardiography, spirometry, and sputum cytologic
studies were also obtained. A small proportion of patients
underwent a positron emission tomography (PET) scan at their
request. All patients had complete pulmonary function testing.
Most patients older than 50 years had a cardiac persantin scan.
All patients underwent a complete resection of the pul-
monary GGO with mediastinal lymph node dissection or
sampling. Histological typing was based on the 2004 World
Health Organization classification.13,14 Disease stages wereFig. 1. A representative picture of a pure ground-glass opacity (GGO) lesion
with clear visuality of the bronchial and vascular structures behind.designated, based on the TNM classification by the American
Joint Committee on Cancer and the International Union
Against Cancer.15 The new classification of lung adenocarci-
nomadproposed by International Association for the Study of
Lung Cancer (IASLC), the American Thoracic Society (ATS),
and the European Respiratory Society (ERS)dwas used for
histological classification.16
For statistical analysis of survival, the Kaplan-Meier
method with a log-rank test and the Cox proportional hazard
model were used. All statistical analyses were performed by
using SPSS software (Version 19.0; SPSS Inc., Chicago, IL,
USA).
3. Results
Fifty patients were eligible and were included in the study.
There were 46 (92.0%) patients who had malignant lesions
and only four (8.0%) patients who had benign lesions. Table 1
summarizes the clinical characteristics of the patients. Most
patients in both groups were nonsmokers. For five patients in
the malignant group, two patients had gastric cancers, one
patient had breast cancer, one patient had tonsillar cancer, and
one patient had lymphoma. The only patient with a previous
malignancy in the benign group had breast cancer.
The mean interval between the time of the first CT scan and
the operation was 4.56 months (Table 2), and the time range
was 0.13e4.3 months. Forty-three (86%) patients underwent
surgery almost immediately after the GGO lesion was detected
by the initial HRCT scan. The remaining seven patients un-
derwent surgery after the second HRCT performed 3 months
later. Of these seven patients, four patients remained stable
(the follow-up times were 8.1 months, 17.9 months, 3.46
months, and 16 months), but the cancer of the other three
patients had progressed by the second HRCT (the follow-up
times were 11.36 months, 31.9 months, and 32.4 months).
Table 3 lists the surgical interventions used for these pa-
tients. Most patients received an intraoperative diagnosis by
frozen section. Only five patients received a preoperative tis-
sue proof either by CT-guided biopsy or by bronchoscopic
transbronchial lung biopsy. Thirty-nine (84.8%) of 46 patients
diagnosed with lung cancer received a lobectomy, whereas the
remaining seven (15.2%) patients underwent a sublobar
resection. Wedge resection was performed in four patients
with benign lesions. The right upper lobe and left upper lobe
were the most common sites for lung cancer tumors. No sur-
gical mortality occurred and there were only three complica-
tions: one patient had postoperative upper gastrointestinal
bleeding and two patients had prolonged chest tube insertion
because of a persistent air leak. The overall complication rate
was low at 6%.
Table 4 lists the pathological characteristics of the 46 pa-
tients with lung cancer. The most common histological pattern
was the papillary predominant type (52.2%), followed by the
acinar predominant type (28.3%) and the lepidic predominant
type (17.4%). One patient had an adenocarcinoma mixed with
small-cell carcinoma. There was no adenocarcinoma in situ or
minimally invasive adenocarcinomas identified in our cohort.
Table 1
Clinical characteristics of all 50 patients with pulmonary ground-glass
opacities.
Character Type of lesion
Malignant
(n ¼ 46)
Benign
(n ¼ 4)
Total
(n ¼ 50)
Age (y)
Mean 60.28 48.50 59.34
Standard deviation 11.82 9.15 11.99
Range 40e83 38e60 38e83
Sex
Male 23 1 24
Female 23 3 26
Smoker
Yes 5 1 6
No 31 3 34
Unknown 10 0 10
Medical comorbidities
Hypertension 12 1 13
Diabetes mellitus 8 0 8
Coronary artery disease 3 0 3
Hyperlipidemia 2 0 0
Chronic obstructive lung disease 2 0 0
Previous malignancy 5 1 6
Table 3
Surgical intervention and complications.
Surgical intervention Malignant
(n ¼ 46)
Benign
(n ¼ 4)
Total
(n ¼ 50)
Biopsy proved prior to the operation
Yes 5 0 5
No 41 4 45
Operative extent
Lobectomy 39 0 39
Sublobar resection 7 4 11
Method
Thoracotomy 40 3 43
VATS 6 1 7
Lymph node dissection
Yes 44 1 45
No 2 3 5
Location
RUL 18 1 19
RML 3 0 3
RLL 5 0 5
LUL 12 1 13
LLL 7 2 9
Complication
Yes 3a 0 3
No 43 4 47
LLL ¼ left lower lobe; LUL ¼ left upper lobe; RLL ¼ right lower lobe;
RML ¼ right middle lobe; RUL ¼ right upper lobe; VATS ¼ video-assisted
thoracoscopic surgery.
a The complications were one patient with gastrointestinal bleeding and two
patients with prolonged air leaks.
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infiltration, angiolymphatic spreading, perineural invasion,
and tumor necrosis. Two patients were diagnosed as having
PL2 visceral pleural invasion and seven patients were diag-
nosed as having PL1 visceral pleural invasion. The patients’
stage was placed at T2aN0M0 (Stage IB). The other 43 pa-
tients were placed at T1a-bN0M0 (Stage IA). There was no
nodal involvement in any of the 46 patients.
Table 5 lists the pathological characteristics of the four
benign tumors. All four tumors were less than 20 mm. There
were two cases of hyalinized granulomas, one case of mild
fibrosis, and one case of necrotizing granulomatous inflam-
mation with cryptococcus infection.
The median follow-up time was 4.46 years (range,
2.77e6.75 years), and the five-year overall survival rate for the
patients was 97.6% (Fig. 2). During the follow-up period, only
one patient died of a disease other than lung cancer, making
the disease-specific survival rate 100%. There was also no
evidence of disease recurrence during the follow-up period
and the disease-free survival rate was 100%.
4. Discussion
The addition of chest CT to an otherwise routine physical
checkup has increased the number of patients being diagnosedTable 2
Time interval between the first computed tomography
examination and the operation.
Time (mo)
Mean 4.56
Standard deviation 8.66
Median 1.00
Range 0.13e34.03with GGO lesions. However, there is no widely accepted
definition of a GGO lesion. In our study, lesions in which
vascular structures were recognized were defined as GGO, and
tumors with less than 50% solid part at the maximal diameter
were included.
Pulmonary GGOs are reportedly slow-growing tumors. The
current strategy for the management of GGOs remains
controversial. During a ten-year period, Min et al17 demon-
strated a stepwise evolution from a focal pure pulmonary GGO
to an invasive lung adenocarcinoma. Yoshida et al18 report that
GGOs are slow growing and frequently remain unchanged for
several years; therefore, they recommend a watchful waiting
strategy for pulmonary GGO lesions. Detterbeck et al19 stated
that surgical intervention is advised if a pure GGO lesion is
more than 10 mm in diameter or if it presents with a solid
component. In our cohort, most patients underwent surgery
almost immediately after the first chest CT examination. Of
the few patients who chose to undergo more than one CT,
more than one-half of them presented with no interval change.
In the current study, we presented the surgical outcomes of
GGOs. Only five (10%) of 50 patients underwent CT-guided
biopsy or bronchoscopic biopsy to obtain pathological proof
prior to surgery. The remaining patients had no preoperative
biopsy for a variety of reasons such as difficult surgical
approach because of a tumor’s small size or location, and
because of the risks of complications and tumor seeding. Of
the 50 patients with GGO lesions, 46 (92%) of the patients had
malignant tumors. This further supports that the likelihood of
malignancy is extremely high in patients with GGOs.
Table 4
Pathological features of 46 patients with malignant tumors.
Variables Number of
patients (n ¼ 46)
(%)
Tumor size (mm)
20 39 84.7
>20, 30 7 5.3
Grade of differentiation
Well 11 23.9
Moderate 35 76.1
Poor 0 0
Histology
Lepidic predominant 8 17.4
Acinar predominant 13 28.3
Papillary predominant 24 52.2
Micropapillary predominant 0 0
Solid predominant 0 0
Mixed with small cell carcinoma 1 2.1
Lymphocytic infiltration
Marked 1 2.1
Moderate 8 17.4
Minimal 20 43.5
Absent 17 37.0
Angiolymphatic spreading
Present 1 2.1
Absent 45 97.9
Perineural invasion
Present 0 0
Absent 46 100
Visceral pleura involvement
PL2 2 4.3
PL1 7 15.2
PL0 37 80.5
Tumor necrosis
Moderate 4 8.7
Minimal 5 10.8
Absent 37 80.5
Stage
T1aN0M0 31 67.4
T1bN0M0 6 13.0
T2aN0M0 9 19.6
Fig. 2. Cumulative probability of overall survival in 46 patients with lung
cancer. The 5-year overall survival rate is 97.6%. The follow-up time is
2.77e6.75 years (mean: 4.46 years).
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using the new IASLC/ATS/ERS (The International Associa-
tion for the Study of Lung Cancer, American Thoracic Society,
and European Respiratory Society) classification for lung
adenocarcinoma.20,21 In patients with Stage I lung adenocar-
cinomas, Yoshizawa et al20 reported that the frequencies of
lepidic, acinar, papillary, micropapillary, and solid predomi-
nant patterns were 5.6%, 45.1%, 27.8%, 2.3%, and 13.0%,
respectively. In Stages IeIV lung adenocarcinomas, Warth
et al21 reported that the frequencies of lepidic, acinar, papil-
lary, micropapillary, and solid predominant patterns wereTable 5
Pathology of benign tumors (n ¼ 4).
Tumor size (mm)
20 4
>20, 30 0
Pathology
Hyalinized granuloma 2
Mild fibrosis 1
Necrotizing granulomatous inflammation with cryptococcal infection 18.1%, 42.5%, 4.7%, 6.8%, and 37.6%, respectively. In our
current cohort of GGO lesions of 3 cm or less, the frequencies
of lepidic, acinar, and papillary predominant patterns were
17.4%, 28.3%, and 52.2%, respectively. No micropapillary
predominant or solid predominant pattern were identified in
our study.
Park et al22 reported an excellent prognosis in a cohort of
58 patients with malignant pure GGOs who underwent sur-
gical resection. There was no incidence of local recurrence or
metastasis occurring in any of these patients after 24 months
of follow up. Kondo et al23 and Ichiki et al24 also demonstrated
a 100% five-year survival rate for patients with resected ma-
lignant GGO lesions. In our study, the median follow-up time
was 4.46 years after surgery. No procedure-related deaths or
complications were observed. Of the 46 patients with malig-
nant tumors, only one patient died of another cause. The
overall survival, disease-free survival, and disease-specific
survival were extremely good in our patients with GGO who
were treated with surgery. We also demonstrated that surgery
for GGO patients can be conducted in a safe manner.
There were some limitations in our study. It is retrospective
in nature and the number of cases was rather small. Selection
bias may exist when choosing patients with GGO for surgery.
A longer follow-up time is also needed. We were also lacking
data concerning patients who opt to follow-up their GGOs for
an extended duration.
In conclusion, there is a high percentage of malignancy
associated with pulmonary GGOs. However, the prognosis for
the patients undergoing surgical resection is excellent. Of the
various alternatives available for medical treatment of GGOs,
surgery appears to be one of the best options. Further study is
necessary to define more effectively GGO lesions and estab-
lish guidelines to treat the patients with GGOs detected by
HRCT.
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